Semaglutide Results Timeline: What the Evidence Shows and When

What STEP 1 tells us about early versus later results

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity or overweight plus at least one weight-related condition to either semaglutide 2.4mg or placebo, over 68 weeks. The average weight loss in the semaglutide group was around 14.9%, roughly 15kg from a starting weight near 100kg. That figure, quoted widely, tells you where treatment can take people. It says less about when.

The trial's weight-loss curve is instructive. Progress was steepest between weeks 8 and 36, once participants had moved through the dose escalation and reached higher therapeutic doses. The first eight weeks, when doses are at their lowest, showed more modest reductions. That pattern matters because people starting treatment often check the scales at week two or three, see a small number, and worry the medicine isn't working. For most, it is, the early weeks are doing something important even when the scales are slow to confirm it.

Appetite suppression tends to arrive before the weight loss does. Most people report eating noticeably less, feeling full sooner, and thinking about food less often within the first couple of weeks. The first week on semaglutide rarely produces dramatic scale movement, but something is usually shifting in appetite. That early signal is worth paying attention to.

The dose ladder and why the timeline isn't linear

Semaglutide for weight management follows a step-up schedule (0.25mg, then 0.5mg, then 1.0mg, then 1.7mg, then 2.4mg) with roughly four weeks at each level before increasing. That means most people don't reach the licensed maintenance dose until around month five. The time it takes Wegovy to work is therefore tied directly to this titration structure: results during months one and two reflect a fraction of the eventual dose.

This is a deliberate design choice. Slower escalation reduces gastrointestinal side effects (nausea, loose stools, indigestion) which are most pronounced when doses increase. The first month's job is adjustment. The clinical work happens later. People who feel impatient at week four are usually at 0.5mg; the patients in the STEP 1 trial who lost 15% were largely doing so from around month four onward, once established on higher doses.

The four-week results picture for most people is therefore a starting line, not a midpoint. Comparing your month-one progress to someone's final total is the wrong comparison entirely. Appetite changes at this stage tend to be clearer than scale changes, and both matter clinically.

When results plateau and what that means

Weight loss on semaglutide doesn't continue indefinitely at the same pace. Most trials show the rate of loss slowing and eventually stabilising, a plateau that typically appears between weeks 56 and 72 at the maintenance dose. This is normal physiology: as body weight falls, metabolic rate adapts and fewer calories are required. The medicine hasn't stopped working; the body has found a new equilibrium.

NICE, in its guidance on semaglutide for weight management (TA875), sets a clear benchmark: if less than 5% weight loss has occurred after six months on the maintenance dose, continuing treatment should be reviewed. That threshold exists because the evidence for meaningful health benefit scales with the degree of weight reduction. Reaching a plateau above 5% is a different situation from not responding at all.

For people wondering what to expect at the eight-week mark, the eight-week results page covers the data in detail. And if you're thinking about the longer picture, the question of how long Wegovy treatment lasts is one our prescribers address regularly, because the answer genuinely varies by individual circumstance.

One thing many people feel but rarely say aloud: there's a real frustration in doing everything right and feeling like results are slower than you expected. That frustration is completely understandable, and it tends to ease once the dose reaches therapeutic range and the trajectory becomes clearer. Patience in the first three months is genuinely part of the treatment, not a sign that it isn't working. You can read more about the overall semaglutide results evidence if you want the fuller clinical picture before deciding whether to proceed, and our Wegovy treatment page covers eligibility and what the consultation involves.

The cost of Wegovy is also a practical consideration at this stage, understanding what a full course of treatment involves, over time, is part of making an informed decision. It's worth reading the detail rather than comparing headline monthly figures.